ClinicalTrials.gov
ClinicalTrials.gov Menu

Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01211652
Recruitment Status : Completed
First Posted : September 29, 2010
Last Update Posted : January 29, 2013
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The purpose of this study is to assess in general population NSAID and gastroprotective agent utilization and compliance in elderly people.

Condition or disease
Healthy

Study Type : Observational
Actual Enrollment : 8186 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Utilization and Compliance in Elderly Patients Taking Non-steroidal Anti-inflammatory Drug (NSAID) in France
Study Start Date : October 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : November 2010

Group/Cohort
1



Primary Outcome Measures :
  1. NSAID Treatment Compliance [ Time Frame: At the end of month 1 ]
  2. Gastroprotective agent compliance (Girerd Questionnaire) [ Time Frame: At the end of month 1 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Community sample
Criteria

Inclusion Criteria:

  • French people > 65 years old, part of Kantar Health Access Santé panel

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01211652


  Show 3511 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Dr Jean-Francois Bretagne Service gastro-enterologie et hepatologie CHRU Pontchaillou 35033 RENNES cedex France
Study Chair: Pr Gerard Thiefin Service Hepato-Gastroenterologie CHU Reims 51092 REIMS cedex France
Principal Investigator: Mrs Genevieve BONNELYE KantarHealth - France138, avenue Marx Dormoy 92120 Montrouge cedex

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01211652     History of Changes
Other Study ID Numbers: NIS-PFR-DUM-2010/1
First Posted: September 29, 2010    Key Record Dates
Last Update Posted: January 29, 2013
Last Verified: January 2013

Keywords provided by AstraZeneca:
Compliance
France
Self-administered questionnaire to patients

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antirheumatic Agents